Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis' Operating Revenues Slide 8 Percent in First Half of 2013

NEW YORK (GenomeWeb News) – Genome engineering firm Cellectis on Thursday reported that its total operating revenues slipped 8 percent year over year during the first half of 2013.

For the first six months of the year, the Paris-based firm brought in €6.9 million ($9.4 million) in operating revenues, compared to €7.5 million during the first half of 2012. Operating revenues for the recently completed period comprised €2.8 million in sales, down from €3.1 million a year ago, and €4.1 million in other operating revenues, down from €4.4 million a year ago.

Cellectis' net loss for H1 2013 widened 55 percent to €17.8 million from €11.5 million in H1 2012. Adjusting for foreign currency translation, Cellectis' comprehensive loss increased to €18.5 million in the first six months of the year, compared to €11.1 million a year ago.

The company said that R&D costs for the period rose 5 percent to €11.1 million from €10.6 million a year ago, while its SG&A costs were up 56 percent to €12.5 million from €8.0 million.

Cellectis had €9.5 million in cash and cash equivalents as of June 30.

The firm said that it anticipates a reduction in its cash burn rate — which it said was high for the first half of the year — by the end of the 2013. Cellectis added that in order to "ensure adequate financing" to fulfill its needs in the coming months, it is considering selling some patents that are not strategic to the firm, as well as other assets. It also is considering a capital raise "via the contingent equity line with Kepler Capital Markets," a financial services firm.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.